Yervoy (ipilimumab) / BMS 
Welcome,         Profile    Billing    Logout  
 197 Diseases   398 Trials   398 Trials   21826 News 


«12...5051525354555657585960...266267»
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Phase classification:  Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL (clinicaltrials.gov) -  Feb 15, 2023   
    P1,  N=6, Completed, 
    Phase classification: P1/2 --> P1
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, Combination therapy:  Widespread vitiligo and poliosis following ipilimumab-nivolumab combination therapy. (Pubmed Central) -  Feb 14, 2023   
    We report a unique case of severe vitiligo and poliosis that involved total body surface area in a Caucasian man with dark complexion, resembling albinism. Further studies are warranted to evaluate the severity of dermatologic side effects with combination immune checkpoint inhibitor therapy.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Imfinzi (durvalumab) / AstraZeneca, Yervoy (ipilimumab) / BMS
    Trial primary completion date, Checkpoint inhibition, Metastases:  Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors (clinicaltrials.gov) -  Feb 14, 2023   
    P1/2,  N=100, Recruiting, 
    Exploratory PD-L1, TMB, and mut analysis may provide insight into the clinical benefit of 1L dual immunotherapy by THS. Trial primary completion date: Oct 2023 --> Oct 2024
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Biomarker, Review, Journal, Checkpoint inhibition, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker:  Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress. (Pubmed Central) -  Feb 14, 2023   
    For unresectable disease, platinum and pemetrexed chemotherapy has been the only standard of care in first line for more than two decades, while no standard treatments have been approved in subsequent lines...In fact, the combination of ipilimumab plus nivolumab has been approved in first line setting...Consequentially, several potential biomarkers predictive of response to immunotherapy in patients with MM have been identified, also if all these elements need to be further investigated and prospectively validated. In this paper, the main evidences about clinical efficacy of ICIs in MM and the literature data about the most promising predictive biomarkers to immunotherapy are reviewed.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, PD(L)-1 Biomarker, IO biomarker:  Temozolomide combined with ipilimumab plus nivolumab enhances T cell killing of MGMT-expressing, MSS colorectal cancer cells. (Pubmed Central) -  Feb 14, 2023   
    Our results indicate that TMZ sensitizes MSS, MGMT-expressing CRC cells to ipilimumab + nivolumab ICI. Importantly, this suggests that TMZ-mediated sensitization to ipilimumab + nivolumab appears independent of MGMT status and the patient cohort that may benefit from TMZ + ipilimumab + nivolumab may be expanded to CRC patients with MGMT-expressing, MSS tumors.
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, Checkpoint inhibition:  Subclinical Celiac Disease Unmasked by Immune Checkpoint Inhibitor Therapy. (Pubmed Central) -  Feb 13, 2023   
    Although ICI-induced CD is relatively rare, it is essential to consider it in a genetically susceptible patient undergoing treatment with ICI. Patients with known high susceptibility to CD, such as a family history of CD, or with the ancestry of high celiac penetrance (eg, Northern Europe, North Africa, etc), dermatitis herpetiformis, or chronic bowel symptoms, we feel should have celiac panel testing before initiating ICI therapy.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS, ciforadenant (CPI-444) / Corvus Pharma
    Enrollment open:  Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. (clinicaltrials.gov) -  Feb 13, 2023   
    P1b/2,  N=15, Recruiting, 
    Patients with known high susceptibility to CD, such as a family history of CD, or with the ancestry of high celiac penetrance (eg, Northern Europe, North Africa, etc), dermatitis herpetiformis, or chronic bowel symptoms, we feel should have celiac panel testing before initiating ICI therapy. Not yet recruiting --> Recruiting
  • ||||||||||  FDA event, Review, Journal:  FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? (Pubmed Central) -  Feb 12, 2023   
    The Food and Drug Administration (FDA) has, to date, approved nivolumab, pembrolizumab, ramucirumab, nivolumab/ipilimumab, atezolizumab/bevacizumab, as well as tremelimumab/durvalumab, as first- or second-line monoclonal antibodies (mAbs) for unresectable HCC. The present review examines the current state of knowledge, and provides a useful update on the safety and efficacy of these therapeutic agents, thus attempting to define the suitability of each mAb for different patient subgroups.
  • ||||||||||  Journal, Interview:  Development and Verification of an irAEs Self-Reported Interview System(ISRIS) (Pubmed Central) -  Feb 11, 2023   
    However, its detection rate of myocarditis and thyroid, hepatic, and renal dysfunction was low, and there is room for improvement. We are currently developing an ISRIS application that maintains sensitivity and increases specificity to allow for early detection of irAEs at home.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal:  A Case of Thoracoscopic Subtotal Esophagectomy for Malignant Esophageal Melanoma (Pubmed Central) -  Feb 11, 2023   
    However, the patient's general condition deteriorated rapidly, and palliative care was implemented at 4 months postoperatively. Surgery is currently the initial choice for resectable primary malignant esophageal melanoma; however, a multidisciplinary treatment strategy, including preoperative adjuvant chemotherapy, should be reconstructed.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment closed, Trial completion date:  J1414: Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (clinicaltrials.gov) -  Feb 10, 2023   
    P2,  N=45, Active, not recruiting, 
    Surgery is currently the initial choice for resectable primary malignant esophageal melanoma; however, a multidisciplinary treatment strategy, including preoperative adjuvant chemotherapy, should be reconstructed. Recruiting --> Active, not recruiting | Trial completion date: Jan 2023 --> Oct 2027
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, Combination therapy:  Combination therapy with immune check point inhibitors and acute kidney injury. (Pubmed Central) -  Feb 10, 2023   
    Patients receiving combination therapy with checkpoint inhibitors are at high risk of AKI, but different causes of AKI should always be considered. Use of PPI concurrently with ICIs is likely to increase the risk of AKI.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, Checkpoint inhibition, Metastases:  Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma. (Pubmed Central) -  Feb 10, 2023   
    40 years experiencing disease progression within 6 months of ICI treatment had increased concentrations of sPDL1 (p = 0.05) and sTIM3 (p = 0.054) at baseline. Young patients with stage IV melanoma may experience shorter progression-free survival upon ICI treatment compared to patients above 40 years and are characterized by fewer basophils and memory T cells in the blood.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases:  Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland. (Pubmed Central) -  Feb 9, 2023   
    P3
    Young patients with stage IV melanoma may experience shorter progression-free survival upon ICI treatment compared to patients above 40 years and are characterized by fewer basophils and memory T cells in the blood. This study showed that nivolumab plus ipilimumab, which represents one of the standard-of-care first-line treatments for intermediate- or poor-risk aRCC patients, is a life-extending and cost-effective treatment option for patients in Switzerland.
  • ||||||||||  TP53-EphA-2-CAR-DC / Chinese PLA General Hospital
    Enrollment change, IO biomarker, Metastases:  Combination of CAR-DC Vaccine and ICIs in Malignant Tumors (clinicaltrials.gov) -  Feb 8, 2023   
    P1,  N=10, Recruiting, 
    Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023 N=20 --> 10
  • ||||||||||  KRAS-EphA-2-CAR-DC / Chinese PLA General Hospital
    Enrollment change, Combination therapy, IO biomarker, Metastases:  CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors (clinicaltrials.gov) -  Feb 8, 2023   
    P1,  N=10, Recruiting, 
    N=20 --> 10 N=20 --> 10